Posterior Uveitis Associated with Cemiplimab.
Sign Up to like & getrecommendations! Published in 2021 at "Ocular immunology and inflammation"
DOI: 10.1080/09273948.2021.1872649
Abstract: PURPOSE The immune checkpoint inhibitors (ICPIs) comprise a class of oncologic immunotherapies. The most recent US Food and Drug Administration-approved ICPI is cemiplimab (Libtayo®). Cemiplimab, like the other ICPIs, blocks checkpoint receptors in order to… read more here.
Keywords: posterior uveitis; treatment; cemiplimab; associated cemiplimab ... See more keywords
Cemiplimab for locally advanced and metastatic basal cell carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2043748
Abstract: ABSTRACT Introduction Locally advanced basal cell carcinoma (laBCC) represents approximatively 1% of all BCCs. Metastatic BCC (mBCC) is even more rare. Most cases are observed in immunocompromised patients, particularly solid organ transplant recipients (OTRs). When… read more here.
Keywords: labcc mbcc; therapy; cemiplimab; cell ... See more keywords
Immunotherapy (Cemiplimab)-Induced Bullous Pemphigoid: A Possible Pitfall in 18F-FDG PET/CT.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical nuclear medicine"
DOI: 10.1097/rlu.0000000000003894
Abstract: ABSTRACT A 78-year-old man with multiple squamous cell carcinomas of the skin underwent 18F-FDG-PET/CT for restaging after 4 cycles of cemiplimab. The scan showed new disseminated FDG-avid skin lesions. Dermatologic examination and biopsy revealed bullous… read more here.
Keywords: bullous pemphigoid; 18f fdg; cemiplimab; fdg pet ... See more keywords
Cemiplimab in advanced cutaneous squamous cell carcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "Dermatologic therapy"
DOI: 10.1111/dth.15184
Abstract: Cemiplimab, a high-affinity, highly potent human monoclonal antibody that binds to the programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) receptor, is the only drug to attain Food and Drug Administration (FDA) approval and marketing authorization from… read more here.
Keywords: squamous cell; cell carcinoma; cutaneous squamous; cemiplimab ... See more keywords
The efficacy and safety of cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: A comparative analysis of retrospective studies versus prospective studies
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15715
Abstract: Cemiplimab has been widely recommended by international guidelines to treat patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). In this study, we conducted a comparative analysis to integrate the efficacy and safety… read more here.
Keywords: locally advanced; metastatic cutaneous; prospective studies; cemiplimab ... See more keywords
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-2609
Abstract: Purpose: This first-in-human study assessed the safety, tolerability, dose-limiting toxicities (DLT), antitumor activity, and pharmacokinetics of cemiplimab, a monoclonal anti-programmed cell death-1 (PD-1), as monotherapy and in combination with hypofractionated radiotherapy (hfRT) and/or cyclophosphamide (CPA)… read more here.
Keywords: patients advanced; human study; first human; combination ... See more keywords
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-23-3883
Abstract: Abstract Purpose: Preclinical data indicate that fianlimab (antilymphocyte activation gene-3) plus cemiplimab (anti–PD-1) enhances antitumor activity. Here, we report prespecified final analyses of the dose-escalation part of a first-in-human, phase 1 study (NCT03005782) of fianlimab… read more here.
Keywords: dose escalation; cemiplimab patients; cemiplimab; monotherapy combination ... See more keywords
Abstract LB366: Fianlimab + cemiplimab in patients (pts) with advanced (adv) melanoma (Mel): Subgroup analyses by blinded independent central review (BICR)
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-lb366
Abstract: Treatment (Tx) with fianlimab (anti-LAG-3) + cemiplimab (anti-PD-1) resulted in a 57% ORR by BICR in pts with adv Mel, with an acceptable risk-benefit profile. Here, we present an efficacy analysis by BICR in subgroups… read more here.
Keywords: mel; fianlimab; bicr; mos ... See more keywords
Abstract CT114: INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab (REGN2810) in newly-diagnosed glioblastoma (GBM) (NCT03491683)
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs18-ct114
Abstract: Despite advances in therapy, glioblastoma (GBM) remains one of the most deadly cancers, with five-year survival under 5%. Newer immunotherapies hold promise in the treatment of GBM, and T cell-enabling therapies may improve progression-free and… read more here.
Keywords: ino 9012; ino 5401; cemiplimab; ino ... See more keywords
Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359211066147
Abstract: Basal cell carcinoma (BCC) is the most common malignancy worldwide. Fortunately, most tumors are localized and easily amenable to surgical resection or locally destructive treatments. However, a subset of BCCs can become locally advanced or… read more here.
Keywords: cell carcinoma; cemiplimab; basal cell;
Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.6003
Abstract: 6003 Background: ISA101b (peltopepimut-S) is a therapeutic vaccine targeting the HPV16 E6/E7 oncoproteins. The synthetic long peptides of ISA101b induce specific expansion of both CD4+ T-helper cells and CD8+ cytotoxic T-cells against E6/7 oncogenes1. Combination… read more here.
Keywords: hpv16; isa101b cemiplimab; patients cps; cemiplimab ... See more keywords